The statement critiques the FDA's decision-making process, particularly its impact on innovation costs, which constitutes public discourse as it addresses a public issue related to regulatory practices and their broader implications.
- The statement does not use harmful language but rather critiques a public agency's practices, aligning with the principle of doing no harm with words. [+1]Principle 1:I will strive to do no harm with my words and actions.
- The statement aims to promote understanding of the FDA's impact on innovation costs, aligning with promoting understanding and empathy. [+1]Principle 3:I will use my words and actions to promote understanding, empathy, and compassion.
- The statement engages in constructive criticism of the FDA without resorting to personal attacks, aligning with the principle of constructive dialogue. [+1]Principle 4:I will engage in constructive criticism and dialogue with those in disagreement and will not engage in personal attacks or ad hominem arguments.
- By highlighting issues with the FDA, the statement uses influence to potentially advocate for better regulatory practices, aligning with societal betterment. [+1]Principle 6:I will use my influence for the betterment of society.
- The statement exercises free speech responsibly by addressing a public issue with integrity. [+1]Principle 7:I will uphold the principles of free speech and use my platform responsibly and with integrity.